Global Bulimia Nervosa Drug Market, By Disorder Type (Purging, Non-Purging), Drug Type (Antidepressants, Antipsychotics, Selective Serotonin Reuptake Inhibitor, Serotonin-Norepinephrine Reuptake Inhibitor, Benzodiazepines, Others), Route of Administration (Oral, Intravenous, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals, Clinics, Homecare, Specialty Centers, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Bulimia Nervosa Drug Market
The bulimia nervosa drug market is expected to gain growth at a potential rate of 5.20% in the forecast period of 2021 to 2028. The increase in the investment in research and development is the factor responsible for the market growth.
Bulimia nervosa is a type of an eating disorder which is portrayed by eating a large amount of food in a short period of time. The disorder is also recognized as bulimia. Bulimia nervosa leads to severall life-threatening and serious complications such as tooth and gum decay, heart problems, anxiety self-injury, dehydration and digestive problems.
The rapid rise in the prevalence of psychological disorders, alcoholism and diabetes is expected to accelerate the market growth in the forecast period of 2021 to 2028. Likewise, the rapid change in the lifestyle and increase in the peer pressure associated with the rise in alcoholism are also predictable to enhance the bulimia nervosa drug market growth. Furthermore, the increase in the incidence and prevalence of the disease and rise in the focus of various organizations to create awareness among people are also projected to drive the market growth rate.
In addition, the technological advancements for efficient treatment and the rapid development in the healthcare expenditure and increase in the government support for the research and development for new and better treatment have are likely to create various new opportunities that will impact this bulimia nervosa drug market growth in the forecast period of 2021 to 2028.
However, the lack of drugs particularly for the treatment of bulimia nervosa and dearth of awareness regarding the treatment options are expected to act as major restraints towards the growth of the bulimia nervosa drug market, whereas high cost of the therapy can challenge the growth of the target market in the above mentioned forecast period.
This bulimia nervosa drug market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the bulimia nervosa drug market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Bulimia Nervosa Drug Market Scope and Market Size
Bulimia nervosa drug market is segmented on the basis of disorder type, drug type, route of administration, distribution channel and end users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of disorder type, the bulimia nervosa drug market can be segmented into purging and non-purging.
- The drug type segment of the bulimia nervosa drug market can be segmented into antidepressants, antipsychotics, selective serotonin reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor, benzodiazepines, and others.
- Based on route of administration, the bulimia nervosa drug market can be segmented into oral, intravenous and others.
- On the basis of distribution channel, the bulimia nervosa drug market can be segmented into hospital pharmacies, retail pharmacies and online pharmacies.
- On the basis of end users, the bulimia nervosa drug market can be segmented into hospitals, clinics, homecare, specialty centers and others.
Bulimia Nervosa Drug Market Country Level Analysis
Bulimia nervosa drug market is analyzed and market size information is provided by country by disorder type, drug type, route of administration, distribution channel and end users as referenced above.
The countries covered in the bulimia nervosa drug market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America leads the bulimia nervosa drug market due to presence of well developed healthcare infrastructure and rise in the prevalence of bulimia nervosa. Asia-Pacific region is expected to expand at a significant growth rate in the forecast period of 2021 to 2028 because of the rise in the awareness regarding mental disorders and increase in the incidence rate of bulimia nervosa.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Bulimia nervosa drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Bulimia Nervosa Drug Market Share Analysis
Bulimia nervosa drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to bulimia nervosa drug market.
The major players covered in the bulimia nervosa drug market report are Allergan, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer, Inc., Johnson & Johnson Services, Inc., Novo Nordisk A/S, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma, Novartis AG, Medtronic, Zydus Cadila, AbbVie Inc, Apotex Inc., Teva Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co., Ltd., F. Hoffmann-La Roche Ltd, and Sun Pharmaceutical Industries Ltd., among other domestic and global players. Bulimia nervosa drug market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.